The global cancer diagnostics market is poised for robust growth, with sales projected to rise from USD 60.4 billion in 2024 to USD 136.7 billion by 2034, reflecting a CAGR of 8.5%. This expansion is fueled by technological advancements, increasing cancer prevalence, and the rising emphasis on early detection.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐍𝐨𝐰 𝐭𝐨 𝐠𝐞𝐭 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: – https://www.futuremarketinsights.com/report-sample#5245502d47422d31303930
𝐊𝐞𝐲 𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬
- Early Cancer Detection & Improved Patient Outcomes
Cancer detection at earlier stages significantly enhances treatment effectiveness, survival rates, and healthcare cost reduction. Governments and healthcare organizations worldwide are promoting awareness programs to encourage routine screening. - Rising Cancer Incidence Worldwide
According to the World Health Organization (WHO) 2022 report, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. Additionally, 53.5 million people were living with cancer within five years of diagnosis, underlining the urgent need for advanced diagnostic solutions. - Technological Innovations Driving Market Expansion
Advances in liquid biopsy, artificial intelligence (AI)-driven diagnostics, and precision medicine are transforming cancer detection and monitoring. These innovations provide greater accuracy, faster results, and minimally invasive testing methods. - Growing Investments in Oncology Research
Increased R&D funding from pharmaceutical companies and governments is accelerating the development of novel diagnostic tools and expanding accessibility to early screening programs worldwide.
𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬
- Market Growth: Projected to reach USD 136.7 billion by 2034, growing at 8.5% CAGR.
- Cancer Burden: WHO reports 1 in 5 people develop cancer in their lifetime, highlighting urgent diagnostic needs.
- Tech Innovations: AI, liquid biopsy, and precision medicine are revolutionizing early detection.
- Investment Surge: R&D and global healthcare spending drive market expansion.
𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 – https://www.futuremarketinsights.com/reports/cancer-diagnostics-market
𝐇𝐨𝐰 𝐢𝐬 𝐚𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐢𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝐛𝐞𝐢𝐧𝐠 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐢𝐧𝐭𝐨 𝐜𝐚𝐧𝐜𝐞𝐫 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬?
Artificial intelligence (AI) is being integrated into cancer diagnostics in various ways, enhancing accuracy, efficiency, and personalization in cancer care. Here are some key applications:
- Analysis of Medical Images: AI algorithms analyze images from mammograms, sonograms, X-rays, MRIs, and tissue samples to detect suspicious areas, often more accurately than the human eye. For example, AI can outline cancer-suspicious areas in prostate MRI scans without human supervision. Google’s AI software has also been shown to reduce false positives in mammogram readings by 6% and false negatives by 9%.
- Early Cancer Risk Prediction: AI can analyze mammograms and other medical data to identify individuals at high risk of developing cancer before it sets in, enabling close monitoring and early intervention. AI algorithms have outperformed standard risk models in predicting breast cancer development.
- Improved Accuracy and Reduced Errors: By helping radiologists accurately identify suspicious areas on scans, AI reduces the chances of missing early cancers and minimizes false positive diagnoses.
- Blood Tests for Cancer Detection: AI-enhanced blood tests can detect cancer more accurately through blood profiling, analyzing ctDNA and miRNA plasma profiles. A novel AI-based technology has been developed for diagnosing lung cancer through blood tests, accurately spotting cancer in 91% of subjects with early-stage disease and 96% with advanced cancer phases.
- Genome Sequencing: AI algorithms analyze a tumor’s genomic sequences to determine its origin, which is particularly useful when cancer has metastasized and the origin is unclear.
- Personalized Treatment Plans: AI can characterize tumors and develop personalized treatments by analyzing a patient’s and cancer cells’ data. AI tools can also predict how a person will respond to various treatments. The National Institute of Health has even built an AI tool that can analyze individual tumor cells and predict their response to a given drug.
- Integration into Diagnostic Workflows: The FDA has approved numerous AI and ML tools for radiology, indicating their growing integration into standard diagnostic procedures.
- Assisting Dietitians: AI tools can help assess patients’ eating patterns and design meal plans. AI-powered apps can estimate the nutrient content of meals based on smartphone photos, improving the accuracy of meal tracking and assessments.
𝐈𝐧-𝐕𝐢𝐭𝐫𝐨 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬, 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬, 𝐚𝐧𝐝 𝐆𝐫𝐨𝐰𝐭𝐡 𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐢𝐨𝐧𝐬 𝐀𝐜𝐫𝐨𝐬𝐬 𝟐𝟎+ 𝐂𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬 – https://www.futuremarketinsights.com/industry-analysis/in-vitro-diagnostics-devices
𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐨𝐟 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Illumina Inc.
- bioMérieux SA
- Siemens Healthineers
- GE Healthcare
- Hologic Inc.
- Agilent Technologies Inc.
- Becton, Dickinson and Company (BD)
- Myriad Genetics Inc.
- Qiagen
𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐨𝐟 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭
By Test Type:
In terms of test type, the industry is divided into- tumor biomarkers tests – (PSA tests, CTC tests, AFP tests, CA tests HER2 tests, BRCA tests, ALK tests, CEA tests, EGFR mutation tests, KRAS mutation tests, others, ultrasound, mammography, MRI scan, PET scan, CT scan, SPECT & others). Biopsy- (needle biopsy, endoscopic biopsy, bone marrow biopsy, other), liquid biopsy, immunohistochemistry and in situ hybridization.
By Indication:
In terms of indication, the industry is segregated into breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others
By End User:
In terms of end user, the industry is segregated into- hospital associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes and others.
By Region:
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
